US-based drug formulation developer Xeris Pharmaceuticals has closed a series C round featuring Mérieux Développement, a subsidiary of healthcare and pharmaceutical holding company Institut Mérieux, at $85m.
Mérieux Développement led the round’s $10m final close, investing together with Wild Basin Investments and unnamed members of Xeris’ management team. The funding was secured alongside a $45m loan agreement with Silicon Valley Bank and Oxford Finance.
Xeris is working on a range of stable drug formulations of peptides, proteins, antibodies or small…
